公开(公告)号：US20150376248A1

公开(公告)日：2015-12-31

申请号：US14765016

申请日：2014-01-31

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Nicholas E. Kurland ,  Vamsi K. Yadavalli

IPC: C07K14/435 ,  G03F7/20 ,  G03F7/26 ,  C07K1/107

CPC classification number: C07K14/43586 ,  C07K1/1072 ,  C07K1/1077 ,  G03F7/038 ,  G03F7/0388 ,  G03F7/20 ,  G03F7/26

Abstract: A natural protein, specifically silk fibroin or sericin, is chemically modified such that it can be rendered photoactive, but which otherwise has similar structure and attributes as silk fibroin or sericin. This chemically modified silk conjugate can be patterned using radiant energy to produce patterned silk materials which may be used for a wide variety of applications such as making micro and nanoparticles of different shapes and functionalities for drug delivery, creating new forms of intricate 3D scaffolds for tissue engineering, and forming substrates for flexible bio-electronics.

Abstract translation: 化学修饰天然蛋白质，特别是丝素蛋白或丝胶蛋白，使其能够呈现光活性，但其具有与丝素蛋白或丝胶蛋白相似的结构和属性。 这种化学改性的丝绸缀合物可以使用辐射能图案化以产生图案化丝材料，其可用于各种应用，例如制备用于药物递送的不同形状和功能的微型和纳米颗粒，为组织创造复杂的3D支架的新形式 工程和形成柔性生物电子基材。

公开(公告)号：US20150112287A1

公开(公告)日：2015-04-23

申请号：US14445566

申请日：2014-07-29

Applicant: Virginia Commonwealth University ,  The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Inventor： Gary Bowlin ,  David Simpson ,  James Bowman ,  Stephen Rothwell

IPC: A61L15/28 ,  A61L15/32 ,  A61L15/44 ,  A61L15/38

CPC classification number: A61L15/28 ,  A61L15/32 ,  A61L15/38 ,  A61L15/44 ,  A61L2300/252 ,  A61L2300/254 ,  A61L2300/418 ,  A61L2400/04 ,  Y10T156/10 ,  C08L5/02

Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.

Abstract translation: 本发明一般涉及优选静电纺丝的葡聚糖纤维和由这种纤维形成的装置。 特别地，这样的装置可以包括与静电纺丝纤维相关联的感兴趣的物质（例如治疗物质）。 当暴露于液体时，电纺纤维立即溶解，感兴趣的物质被释放到液体中。 示例性装置包括由电纺丝葡聚糖纤维形成的绷带和促进止血的相关药物，例如凝血酶和纤维蛋白原。

公开(公告)号：US20150107589A1

公开(公告)日：2015-04-23

申请号：US14399317

申请日：2013-04-23

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Phillip Worth Longest ,  Michael Hindle ,  Yeon-Ju Son ,  S. R. B. Behara ,  Dale Farkas

IPC: A61M11/00 ,  A61K9/14 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61M15/00 ,  A61K31/137

CPC classification number: A61M11/003 ,  A61K9/14 ,  A61K31/137 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61M11/005 ,  A61M11/02 ,  A61M15/0021 ,  A61M15/0028 ,  A61M15/003 ,  A61M15/0045 ,  A61M15/0086 ,  A61M2202/0092 ,  A61M2202/064 ,  A61M2205/0238 ,  A61M2205/583 ,  A61M2206/10 ,  A61M2209/02

Abstract: A dry powder inhaler (DPI) device has a flow passage with a three-dimensional (3D) rod array. The rod array includes multiple rows each having multiple unidirectional rods. The rows are spaced apart along a primary direction of air flow and are staggered. A viewing window to the capsule chamber allows viewing of the capsule's position within the chamber which provides visual feedback of inhalation flow rate to the user during inhalation. The capsule chamber may orient the capsule parallel to a primary direction of air flow or perpendicular to a primary direction of air flow and provide capsule motion in a plane which is perpendicular to the primary direction of air flow.

Abstract translation: 干粉吸入器（DPI）装置具有具有三维（3D）棒阵列的流动通道。 杆阵列包括多排，每排具有多个单向杆。 这些排沿空气流的主要方向间隔开并交错。 到胶囊室的观察窗口允许观察胶囊在腔室内的位置，其在吸入期间向使用者提供吸入流速的视觉反馈。 胶囊室可以使胶囊平行于气流的主要方向或垂直于空气流的主要方向定向胶囊，并且在垂直于空气流的主要方向的平面中提供胶囊运动。

公开(公告)号：US08980908B2

公开(公告)日：2015-03-17

申请号：US14287254

申请日：2014-05-27

Applicant: Virginia Commonwealth University

Inventor： Yan Zhang ,  Dana E. Selley ,  William Dewey

IPC: A61K31/485 ,  C07D489/08 ,  G01N33/53

CPC classification number: C07D489/08 ,  G01N33/53 ,  G01N33/9486 ,  G01N2500/04

Abstract: Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction, as well as in the treatment of opioid induced constipation (OIC).

Abstract translation: 提供了μ阿片受体（MOR）的选择性非肽拮抗剂及其使用方法。 拮抗剂可以用于例如在竞争性结合测定中鉴定MOR激动剂，并且用于治疗与其中涉及MOR的成瘾有关的病症，例如， 海洛因，处方药和酒精成瘾，以及治疗阿片样物质诱发便秘（OIC）。

公开(公告)号：US08946254B2

公开(公告)日：2015-02-03

申请号：US14371075

申请日：2013-01-10

Applicant: Virginia Commonwealth University

Inventor： Yan Zhang ,  Kurt F. Hauser ,  Dana E. Selley

IPC: A61K31/485 ,  C07D489/08

CPC classification number: A61K47/481 ,  A61K31/485 ,  A61K47/55 ,  C07D489/08 ,  A61K2300/00

Abstract: Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine receptor 5 (CCR5), are used for the treatment of neurological disorders such as those associated with AIDS.

公开(公告)号：US08906908B2

公开(公告)日：2014-12-09

申请号：US13680710

申请日：2012-11-19

Applicant: Research Triangle Institute ,  Dignity Health ,  Virginia Commonwealth University

Inventor： F. Ivy Carroll ,  Bruce E. Blough ,  Hernan A. Navarro ,  S. Wayne Mascarella ,  Ana Zamfira Muresan ,  M. Imad Damaj ,  Ronald J. Lukas

IPC: C07D265/32 ,  A61K31/5375

CPC classification number: C07D265/32 ,  A61K31/5375

Abstract: The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.

Abstract translation: 本发明提供能够抑制一种或多种单胺再摄取和/或在烟碱型乙酰胆碱受体上作为拮抗剂的羟基安非他丁类似物。 所述化合物可以选择性地结合一种或多种单胺转运蛋白，包括用于多巴胺，去甲肾上腺素和5-羟色胺的单胺转运蛋白和/或可以选择性地结合一种或多种烟碱型乙酰胆碱受体亚型。 这些化合物可用于治疗对单胺水平的修饰和/或烟碱乙酰胆碱受体的拮抗作用有反应的病症，包括药物依赖性，抑郁症和肥胖症。

公开(公告)号：US20140228436A1

公开(公告)日：2014-08-14

申请号：US14253982

申请日：2014-04-16

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Martin MANGINO

IPC: A61K31/191 ,  A61K31/08

CPC classification number: A61K31/191 ,  A01N1/0221 ,  A61K31/08

Abstract: An organ protectant solution which is intravenously administered includes a high concentration of cell-impermeant molecules and at least one oncotic agent. The cell-impermeant molecules preferentially load into the interstitial space and the oncotic agent(s) is/are restricted to the vasculature space. Together, they promote transfer of water from cells to interstitium and into the capillaries, thereby preventing or reducing cell swelling, and maintaining blood circulation and oxygenation of tissues. The organ protectant solution extends the “Golden Hour” for traumatic and/or hemorrhagic shock patients, thereby allowing more time for those patients to reach a point of care facility to receive medical treatment.

Abstract translation: 经静脉内施用的器官保护剂溶液包括高浓度的细胞不渗透分子和至少一种肿瘤剂。 细胞不饱和分子优先加载到间质空间中，并且肿瘤剂限于脉管系统空间。 它们一起促进水从细胞转移到间质并进入毛细血管，从而预防或减少细胞肿胀，并维持组织的血液循环和氧合。 器官保护剂溶液延长了创伤性和/或出血性休克患者的“黄金时段”，从而允许更多的时间让这些患者到达护理设施点接受治疗。

公开(公告)号：US20130310779A1

公开(公告)日：2013-11-21

申请号：US13952186

申请日：2013-07-26

Applicant: Virginia Commonwealth University

Inventor： Gary Wnek ,  Marcus E. Carr, JR. ,  Gary Bowlin ,  Kelman I. Cohen ,  Kevin R. Ward ,  Wayne Barbee ,  Rao Ivatury

IPC: A61L26/00

CPC classification number: A61L26/0061 ,  A61B17/0057 ,  A61B17/122 ,  A61B17/132 ,  A61B2017/00659 ,  A61F13/0269 ,  A61K9/0048 ,  A61L15/22 ,  A61L24/106 ,  A61L24/108 ,  A61L2400/04

Abstract: High-pressure bleeding wounds (and other bleeding wounds) may be treated by applying direct pressure directly in the bleeding wound, such as by applying a back pressure in a confined space around and in the wound. Certain substances and articles may be inserted into the wound, and the wound may be enclosed with that substance or article (such as a hemostatic substance, which may be polymeric), by swelling on contact with molecules (such as water molecules in the blood) encountered in the wound, generates the desired pressure to stop or at least reduce the bleeding without the detrimental effects of a tourniquet. Clot-inducing substances may be introduced into the wound contemporaneously with direct pressure application directly in the wound. Compressible and non-compressible wounds are treated. Treatment stops bleeding without producing pressure injury or ischemic damage. Medical devices using this technology are provided, including removable, biodegradable, medic-administrable devices.

Abstract translation: 可以通过直接对出血伤口施加直接压力来治疗高压出血性伤口（和其他出血性伤口），例如通过在围绕和缠绕的受限空间中施加背压。 某些物质和制品可以插入到伤口中，并且伤口可以与该物质或制品（例如可以是聚合物的止血物质）一起被封闭，通过与分子（例如血液中的水分子）接触而膨胀， 在伤口中遇到，产生所需的停止压力或至少减少出血，而不会有止血带的不利影响。 可以直接在伤口中直接施加压力诱导物质同时引入伤口。 可压缩和不可压缩的伤口被处理。 治疗停止出血而不产生压力损伤或缺血性损伤。 提供使用此技术的医疗设备，包括可拆卸，可生物降解的医疗管理设备。

公开(公告)号：US12291621B2

公开(公告)日：2025-05-06

申请号：US17621278

申请日：2020-06-25

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Massimo Bertino ,  Tyler Selden

IPC: C08J9/28

Abstract: Drying polar solvents which do not form hydrogen bonds with a wet gel or aerogel, or eutectics or solvent mixtures with the drying solvents, are utilized in a solvent exchange with wet gels used in the formation of aerogels. Preferably the drying solvents are non-polar solvents. The drying solvent or solvent mixtures results in profoundly less shrinkage, thereby allowing for the production of aerogels of preferred materials properties.

公开(公告)号：US20250064971A1

公开(公告)日：2025-02-27

申请号：US18727821

申请日：2023-02-03

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Qingguo XU ,  Chaolong QIN ,  Tuo MENG ,  Aji Alex Moothedathu RAYNOLD ,  Matthew BANKS

IPC: A61K47/69 ,  A61K47/54

Abstract: A method of delivering an active ingredient to a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a formulation comprising biodegradable, polymeric microparticles and an active ingredient selected from the group consisting of levo-alpha-acetylmethadol (LAAM), nor-LAAM, and dinor-LAAM, wherein the active ingredient is part of a hydrophobic ion-pairing (HIP) complex and wherein the HIP complex is associated with the microparticles. Sustained release formulations containing an active ingredient are also provided.